未找到相关数据
Pertuzumab plus trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway
被引：17
作者：
Hurwitz, Herbert
Raghav, Kanwal Pratap Singh
Burris, Howard A.
Kurzrock, Razelle
Sweeney, Christopher
Meric-Bernstam, Funda
Vanderwalde, Ari M.
Spigel, David R.
Bose, Ron
Fakih, Marwan
Swanton, Charles
Guo, Shuangli
Bernaards, Coen
Beattie, Mary Stanley
Sommer, Nicolas
Hainsworth, John D.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Tennessee Oncol PLLC, Nashville, TN USA
[5] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
[6] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[7] West Canc Ctr, Memphis, TN USA
[8] Washington Univ, Sch Med, St Louis, MO USA
[9] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[10] Francis Crick Inst, London, England
[11] Genentech Inc, San Francisco, CA 94080 USA
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.676
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
676
引用
收藏
页数：2
相关论文